ALLO - Allogene Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
ALLO price evolution
ALLO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $180.96 | $61.33 | $93.45 | |
| Short term investments | $273.96 | $333.82 | $365.54 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $304.42 | $457.12 | $395.36 | $459.12 |
| Long term investments | $1.13 | $15.12 | $3.65 | |
| Property, plant & equipment | $135.3 | $150.47 | $160.41 | $163.18 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $189.76 | $190.99 | $183.72 | |
| Total investments | $275.1 | $348.94 | $369.19 | |
| Total assets | $589.12 | $646.88 | $586.35 | $642.84 |
| Current liabilities | ||||
| Accounts payable | $5.51 | $12.94 | $5.78 | $5.9 |
| Deferred revenue | $0.09 | $0.09 | ||
| Short long term debt | ||||
| Total current liabilities | $32.57 | $37.3 | $30.89 | $37.08 |
| Long term debt | ||||
| Total noncurrent liabilities | $94.54 | $94.09 | $93.53 | |
| Total debt | ||||
| Total liabilities | $125.37 | $131.84 | $124.98 | $130.6 |
| Shareholders' equity | ||||
| Retained earnings | -$1759.88 | -$1693.59 | -$1627.23 | -$1562.23 |
| Other shareholder equity | $0.16 | -$0.78 | -$0.93 | -$0.95 |
| Total shareholder equity | $515.04 | $461.37 | $512.23 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $93.45 | $72.2 | $183.61 | $192.8 |
| Short term investments | $365.54 | $455.42 | $283.99 | $644.56 |
| Net receivables | $1.7 | $1.8 | $1.9 | $2.8 |
| Inventory | ||||
| Total current assets | $459.12 | $528.82 | $471.32 | $845.13 |
| Long term investments | $3.65 | $71.97 | $370.18 | $207.95 |
| Property, plant & equipment | $163.18 | $196.43 | $181.02 | $160.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $183.72 | $288.25 | $567.31 | $382.7 |
| Total investments | $369.19 | $527.38 | $654.17 | $852.5 |
| Total assets | $642.84 | $817.08 | $1038.63 | $1227.83 |
| Current liabilities | ||||
| Accounts payable | $5.9 | $13.89 | $10.26 | $10.39 |
| Deferred revenue | $0.09 | $0.89 | $0.42 | $38.99 |
| Short long term debt | ||||
| Total current liabilities | $37.08 | $54.52 | $48.17 | $94.32 |
| Long term debt | ||||
| Total noncurrent liabilities | $93.53 | $96.69 | $74.05 | $53.89 |
| Total debt | ||||
| Total liabilities | $130.6 | $151.21 | $122.23 | $148.21 |
| Shareholders' equity | ||||
| Retained earnings | -$1562.23 | -$1235.98 | -$903.35 | -$646.34 |
| Other shareholder equity | -$0.95 | -$9.93 | -$2.57 | $0.27 |
| Total shareholder equity | $512.23 | $665.87 | $916.41 | $1079.62 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.02 | -$0.04 | ||
| Cost of revenue | ||||
| Gross Profit | $0.02 | -$0.04 | ||
| Operating activities | ||||
| Research & development | $50.35 | $52.26 | $54.66 | |
| Selling, general & administrative | $16.09 | $17.27 | $17.22 | |
| Total operating expenses | $71.43 | $69.53 | $85.13 | |
| Operating income | -$71.43 | -$69.5 | -$85.17 | |
| Income from continuing operations | ||||
| EBIT | -$66.36 | -$65 | -$89.26 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$66.36 | -$65 | -$89.26 | |
| Income (for common shares) | -$66.36 | -$65 | -$89.26 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.1 | $0.24 | $38.49 | |
| Cost of revenue | ||||
| Gross Profit | $0.1 | $0.24 | $38.49 | |
| Operating activities | ||||
| Research & development | $242.91 | $256.39 | $220.18 | $192.99 |
| Selling, general & administrative | $71.67 | $79.31 | $74.11 | $65.26 |
| Total operating expenses | $327.83 | $335.69 | $294.28 | $258.24 |
| Operating income | -$327.74 | -$335.45 | -$255.79 | -$258.24 |
| Income from continuing operations | ||||
| EBIT | -$327.26 | -$332.63 | -$257 | -$250.22 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$327.26 | -$332.63 | -$257 | -$250.22 |
| Income (for common shares) | -$327.26 | -$332.63 | -$257 | -$250.22 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$66.36 | -$65 | -$89.26 | |
| Operating activities | ||||
| Depreciation | $3.64 | $3.56 | $3.48 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $13.56 | $11.92 | $15.23 | |
| Total cash flows from operations | -$63.59 | -$55.9 | -$53.71 | |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.18 | ||
| Investments | $74.61 | $22.14 | $67.64 | |
| Total cash flows from investing | $20.75 | $74.61 | $22.13 | $67.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $106.32 | $1.65 | $0.15 | |
| Net borrowings | ||||
| Total cash flows from financing | $110.93 | $108.6 | $1.65 | $0.15 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$31.92 | $119.63 | -$32.12 | $13.91 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$327.26 | -$332.63 | -$257 | -$250.22 |
| Operating activities | ||||
| Depreciation | $14.2 | $14.29 | $10.45 | $7.43 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $65.95 | $83.6 | $80.82 | $65.26 |
| Total cash flows from operations | -$237.73 | -$220.52 | -$184.81 | -$115.09 |
| Investing activities | ||||
| Capital expenditures | -$1.52 | -$5.19 | -$21.45 | -$65.96 |
| Investments | $164.81 | $111.35 | $185.1 | -$439.17 |
| Total cash flows from investing | $163.29 | $106.16 | $163.66 | -$505.12 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $95.69 | $2.95 | $11.96 | $633.59 |
| Net borrowings | ||||
| Total cash flows from financing | $95.69 | $2.95 | $11.96 | $633.59 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $21.25 | -$111.41 | -$9.19 | $13.38 |
News
Fundamentals
| Market cap | $391.77M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 209.50M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.25 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.35 |
| Quick ratio | N/A |